Race Oncology Ltd has released a press release.
Contract to Commence Phase 2 Extramedullary AML Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Prospectus
- Placement closes oversubscribed-Bonus Option Issue launched
- Race investor briefing & updated presentation
- Race Initiates Heart Safety Preclinical Study for Bisantrene
- Second independent study shows Bisantrene inhibits FTO
Later from Racura Oncology
- Race Executes Key Contract for Israel Phase 2 AML Trial
- Race executes Israel AML Phase 2 Trial Contract
- First Patient Dosed in Phase 1b/2 AML Trial
- Zantrene highly effective in Melanoma preclinical study
- Preclinical & Clinical Programs Update
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology